Investor's Business Daily on MSN
Travere, IBD stock of the day, is on path to $3 billion and in a buy zone
Travere Therapeutics is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone after gapping up on an FDA ...
Ligand Pharmaceuticals Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Meet Samuel – Your Personal Investing Prophet. Start a conversation wit ...
Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.
In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings forecasted to grow by 17% annually. In such an environment, identifying potentially ...
In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings expected to grow by 17% per annum in the coming years. In this context, identifying stocks ...
Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs. He discussed the longstanding challenges of treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results